Related Experiment Video

Updated: Jan 14, 2026

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
08:21

Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery

Published on: June 28, 2019

7.3K

Mechanisms and Opportunities of the Arrestin Beta Signaling Pathway in Liver Diseases

Wenchao Zhou1, Hong Xia1, Tian Zeng1

  • 1Hunan Province Key Laboratory of Tumor Cellular & Molecular Pathology, Hengyang Medical School, Cancer Research Institute, University of South China, Hengyang, China.

DNA and Cell Biology
|October 22, 2025
PubMed

Insights

Arrestin beta 1 (ARRB1) and ARRB2 play complex roles in liver diseases. ARRB1 is generally protective, while ARRB2 has dual functions, highlighting the need for targeted therapies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Hepatology

Background:

  • Arrestin beta 1 (ARRB1) and ARRB2 are key adapters in G protein-coupled receptor signaling, implicated in various liver diseases.
  • ARRB1 exhibits protective effects against liver injury and metabolic disorders, but its role in fibrosis is debated due to species differences.
  • ARRB2 demonstrates dual roles, offering protection in some conditions while exacerbating others like autoimmune hepatitis and fibrosis.

Purpose of the Study:

  • To elucidate the distinct and dual roles of ARRB1 and ARRB2 in the context of liver diseases.
  • To investigate the mechanisms underlying the differential functions of ARRB1 and ARRB2 in liver pathology.
  • To explore how structural differences in ARRBs influence their signaling and therapeutic potential.

Main Methods:

  • Comparative analysis of ARRB1 and ARRB2 functions in different liver disease models.
  • Investigation of signaling pathways, including NF-κB/c-Jun N-terminal kinase, apoptosis, and oxidative stress.
  • Examination of structural differences and their impact on signal bias, nuclear interactions, and phosphorylation.

Main Results:

  • ARRB1 demonstrates protective roles in ischemia-reperfusion injury, acute liver injury, and NAFLD by inhibiting apoptosis.
  • ARRB2 shows context-dependent effects, reducing acute hepatitis but promoting fibrosis progression via macrophage activation and collagen deposition.
  • Structural variations in ARRBs may dictate signal bias and nuclear interactions, influencing their pathological roles.

Conclusions:

  • ARRB1 and ARRB2 possess distinct and sometimes opposing roles in liver disease pathogenesis.
  • Understanding the nuanced functions of ARRBs is crucial for developing targeted therapeutic strategies for liver conditions.
  • Further research into ARRB signaling mechanisms could identify novel therapeutic targets for liver disease treatment.
Keywords:
ARRB1ARRB2liver diseasesmolecular mechanismprognostic marker

More Related Videos

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis08:56

Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis

Published on: February 10, 2015

54.4K
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis08:58

Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis

Published on: March 11, 2017

16.8K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.2K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
17.2K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
12.0K